Therna is advancing programmable RNA medicines across cardiovascular, metabolic, and immunological diseases, alongside single-patient programs for ultra-rare conditions.
Therapeutic Pipeline
Single-Patient Programs
Therna is selectively pursuing single-patient programs for ultra-rare conditions where conventional clinical development is not feasible. These efforts apply the RNA-Logix™ capabilities while generating biological insights that strengthen model performance across the broader pipeline. Opportunistic but purposeful, our single-patient work delivers genuine clinical proof of concept and human data that de-risk the platform while reflecting our commitment to patients with ultra-rare diseases who otherwise have no options.
